The encyclopedia · R&D & Science · Technical decision · 2006–2015
Anil Potti faked cancer research at Duke — patients were treated based on his fraud
Duke's star cancer researcher fabricated gene-expression data for years. His work sent three clinical trials treating real patients — all based on fraud.
Duke University · 2015-11-09
What happened
Anil Potti was a rising star at Duke University — a physician and cancer researcher who claimed to have developed gene-expression signatures that could predict how a patient would respond to specific chemotherapy drugs. His work, published in top journals including Nature Medicine and the New England Journal of Medicine, promised personalized cancer treatment based on genomic analysis. Duke launched three clinical trials treating real cancer patients based on Potti's research.
Doubts emerged in 2007 when statisticians at MD Anderson found Potti's data looked too clean to be real. In 2010 The Cancer Letter revealed Potti had fabricated his Rhodes Scholar claim. Duke suspended the trials; a medical student's 2008 memo — which Duke dismissed — was re-examined. The FDA found one trial lacked a required Investigational New Drug application. Co-researcher Nevins called it 'manipulated data' that could not be chance.
The Office of Research Integrity officially found Potti engaged in research misconduct in November 2015. Eleven of his papers were retracted; Duke's own expert testified roughly 27 of 40 examined papers would need retraction. Duke settled malpractice claims with cancer patients. Potti lost funding, was fired from his next job, and was banned from receiving federal research funds until 2020. The scandal prompted an Institute of Medicine report on oversight of genomic clinical trials.
Why it happened
- Duke and the research community accepted spectacular results without demanding raw data or independent replication, trusting the prestige of the institution and the journals.
- Potti fabricated his credentials — including a false Rhodes Scholarship claim — which should have been caught by basic hiring due diligence.
- When a medical student raised concerns in 2008, Duke dismissed them and did not stop the clinical trials, allowing patients to continue receiving treatment based on fraud.
- Peer review at top journals failed to detect the fabricated data, and the genomics field lacked standard reproducibility checks for microarray analysis.
The lesson
Biomedical data fabrication is not just academic fraud — when results guide clinical trials, fake data means real patients get wrong treatment. One researcher can corrupt an entire institution's work.
Aftermath
The Anil Potti scandal became a landmark case in research integrity. The Institute of Medicine's 2012 report set new standards for validating genomic signatures before clinical use. Duke overhauled its conflict-of-interest practices. The case taught that even prestigious institutions can be fooled by fabricated data, and that the cost of trusting attractive results can be measured in patient harm. Potti returned to medicine, but his research career was destroyed.
Sources
- Anil Potti — Wikipedia (rise at Duke, fabricated data, clinical trials, investigation, retractions, settlements)
- Institute of Medicine — Evolution of Translational Omics (2012 report prompted by the scandal)
spotted an error? The club wants to know.
More like this
Physicist faked room-temp superconductivity — 5 retractions, thesis 21% plagiarized
Biogen pushed aducanumab past a 10-1 FDA panel rejection — three panelists resigned
Stanford president resigned over manipulated images — 5 papers retracted or corrected
Somewhere, someone solved the problem this company failed at. 2nd Opinion →
Comments · 0
Sign in to join the comments.